Research Progress of Arginine Vasopressin_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

FU Zhida , GUAN Yulong.

Department of Extracorporeal Circulation， State Key Laboratory of Cardiovascular Disease， Fu Wai Hospital， National Center for Cardiovascular Diseases， Chinese Academy of Medical Sciences &;
Peking Union Medical College， Beijing 100037， P. R . China;

Corresponding author：

Keywords：

Arginine vasopressin; 　Shock; 　Cardiovascular surgery; 　Extracorporeal circulation

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Abstract： Arginine vasopressin （AVP） is closely related to the pathogenesis of a variety of cardiovascular diseases and kidney diseases. Currently it is often used for the treatment of severe peripheral vasodilatory shock， and particularly beneficial for patients with refractory catecholamine-resistant vasodilatory shock. For some patients who do not have adequate AVP level in plasma after cardiovascular surgery， external low-dose AVP infusion is helpful to decrease the heart rate, and the dosage and duration of catecholamine use. Early initiation of low-dose AVP infusion may be beneficial for postoperative patients’ hemodynamic recovery without adverse complications. More randomized control trials are needed to provide evidence for rational usage， dosage and duration of AVP administration.

Citation： FU Zhida,GUAN Yulong.. Research Progress of Arginine Vasopressin. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2013, 20(1): 87-90. doi: Copy

1.	Kounin G， Bashir Q. Mechanism and role of antidiuretic hormone. Surg Neurol， 2000， 53 （5）：508-510.
2.	Oliver G， Schäfer EA. On the physiological action of extracts of pituitary body and certain other glandular organs：preliminary communication. J Physiol， 1895， 18 （3）：277-279.
3.	Kumar S， Berl T. Vasopressin antagonists in the treatment of water-retaining disorders. Semin Nephrol， 2008， 28 （3）：279-288.
4.	Ali F， Guglin M， Vaitkevicius P， et al. Therapeutic potential of vasopressin receptor antagonists. Drugs， 2007， 67 （6）：847-858.
5.	Habib S， Boyer TD. Vasopressin V2-receptor antagonists in patients with cirrhosis， ascites and hyponatremia. Therap Adv Gastroenterol， 2012， 5 （3）：189-197.
6.	Lemmens-Gruber R， Kamyar M. Vasopressin antagonists. Cell Mol Life Sci， 2006， 63 （15）：1766-1779.
7.	Malay MB， Ashton RC Jr， Landry DW， et al. Low-dose vasopressin　 in the treatment of vasodilatory septic shock. J Trauma， 1999， 47 （4）：699-703.
8.	Gordon AC， Wang N， Walley KR， et al. The cardiopulmonary　 effects of vasopressin compared with norepinephrine in septic shock. Chest， 2012， 142 （3）：593-605.
9.	Carroll TG， Dimas VV， Raymond TT. Vasopressin rescue for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing：a prospective feasibility pilot trial. Pediatr Crit Care Med， 2012， 13 （3）：265-272.
10.	Stadlbauer KH， Wagner-Berger HG， Wenzel V， et al. Survival with full neurologic recovery after prolonged cardiopulmonary resuscitation　 with a combination of vasopressin and epinephrine in pigs. Anesth Analg， 2003， 96 （6）：1743-1749.
11.	Jochberger S， Velik-Salchner C， Mayr VD， et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac　 surgery：a prospective， controlled study. Intensive Care Med， 2009， 35 （3）：489-497.
12.	Argenziano M， Chen JM， Choudhri AF， et al. Management of vasodilatory shock after cardiac surgery：identification of predisposing　factors and use of a novel pressor agent. J Thorac Cardiovasc Surg， 1998， 116 （6）：973-980.
13.	Dünser MW， Mayr AJ， Stallinger A， et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med， 2002， 28 （6）：746-751.
14.	Bomberg H， Bierbach B， Flache S， et al. Endothelin and vasopressin　influence splanchnic blood flow distribution during and after cardiopulmonary bypass. J Thorac Cardiovasc Surg， 2013， 145 （2）：539-547.
15.	Khan TA， Bianchi C， Ruel M， et al. Differential effects on the mesenteric microcirculatory response to vasopressin and　phenylephrine after cardiopulmonary bypass. J Thorac Cardiovasc Surg， 2007， 133 （3）：682-688.
16.	Nagamine Y， Hara M. Intravenous arginine vasopressin for two pediatric cases of pulmonary hypertension after congenital heart surgery. Masui， 2012， 61 （10）：1112-1116.
17.	Alten JA， Borasino S， Toms R， et al. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. Pediatr　Crit Care Med， 2012， 13 （3）：300-304.
18.	Mastropietro CW. Arginine vasopressin in neonates after surgery for congenital heart disease：right from the start? Pediatr Crit Care Med， 2012， 13 （3）：360-361.
19.	Weiner GM， Niermeyer S. Medications in neonatal resuscitation：epinephrine and the search for better alternative strategies. Clin　Perinatol， 2012， 39 （4）：843-855.
20.	Jerath N， Frndova H， Mccrindle BW， et al. Clinical impact of vasopressin infusion on hemodynamics， liver and renal function in pediatric　patients. Intensive Care Med， 2008， 34 （7）：1274-1280.
21.	Cheung DC， Gill RS， Liu JQ， et al. Vasopressin improves systemic hemodynamics without compromising mesenteric perfusion in the resuscitation of asphyxiated newborn piglets：a dose-response study. Intensive Care Med， 2012， 38 （3）：491-498.
22.	Narayen G， Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab， 2012， 16 （2）：183-191.

1. 　Kounin G， Bashir Q. Mechanism and role of antidiuretic hormone. Surg Neurol， 2000， 53 （5）：508-510.
2. 　Oliver G， Schäfer EA. On the physiological action of extracts of pituitary body and certain other glandular organs：preliminary communication. J Physiol， 1895， 18 （3）：277-279.
3. 　Kumar S， Berl T. Vasopressin antagonists in the treatment of water-retaining disorders. Semin Nephrol， 2008， 28 （3）：279-288.
4. 　Ali F， Guglin M， Vaitkevicius P， et al. Therapeutic potential of vasopressin receptor antagonists. Drugs， 2007， 67 （6）：847-858.
5. 　Habib S， Boyer TD. Vasopressin V2-receptor antagonists in patients with cirrhosis， ascites and hyponatremia. Therap Adv Gastroenterol， 2012， 5 （3）：189-197.
6. 　Lemmens-Gruber R， Kamyar M. Vasopressin antagonists. Cell Mol Life Sci， 2006， 63 （15）：1766-1779.
7. 　Malay MB， Ashton RC Jr， Landry DW， et al. Low-dose vasopressin　 in the treatment of vasodilatory septic shock. J Trauma， 1999， 47 （4）：699-703.
8. 　Gordon AC， Wang N， Walley KR， et al. The cardiopulmonary　 effects of vasopressin compared with norepinephrine in septic shock. Chest， 2012， 142 （3）：593-605.
9. 　Carroll TG， Dimas VV， Raymond TT. Vasopressin rescue for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing：a prospective feasibility pilot trial. Pediatr Crit Care Med， 2012， 13 （3）：265-272.
10. 　Stadlbauer KH， Wagner-Berger HG， Wenzel V， et al. Survival with full neurologic recovery after prolonged cardiopulmonary resuscitation　 with a combination of vasopressin and epinephrine in pigs. Anesth Analg， 2003， 96 （6）：1743-1749.
11. 　Jochberger S， Velik-Salchner C， Mayr VD， et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac　 surgery：a prospective， controlled study. Intensive Care Med， 2009， 35 （3）：489-497.
12. 　Argenziano M， Chen JM， Choudhri AF， et al. Management of vasodilatory shock after cardiac surgery：identification of predisposing　factors and use of a novel pressor agent. J Thorac Cardiovasc Surg， 1998， 116 （6）：973-980.
13. 　Dünser MW， Mayr AJ， Stallinger A， et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med， 2002， 28 （6）：746-751.
14. 　Bomberg H， Bierbach B， Flache S， et al. Endothelin and vasopressin　influence splanchnic blood flow distribution during and after cardiopulmonary bypass. J Thorac Cardiovasc Surg， 2013， 145 （2）：539-547.
15. 　Khan TA， Bianchi C， Ruel M， et al. Differential effects on the mesenteric microcirculatory response to vasopressin and　phenylephrine after cardiopulmonary bypass. J Thorac Cardiovasc Surg， 2007， 133 （3）：682-688.
16. 　Nagamine Y， Hara M. Intravenous arginine vasopressin for two pediatric cases of pulmonary hypertension after congenital heart surgery. Masui， 2012， 61 （10）：1112-1116.
17. 　Alten JA， Borasino S， Toms R， et al. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. Pediatr　Crit Care Med， 2012， 13 （3）：300-304.
18. 　Mastropietro CW. Arginine vasopressin in neonates after surgery for congenital heart disease：right from the start? Pediatr Crit Care Med， 2012， 13 （3）：360-361.
19. 　Weiner GM， Niermeyer S. Medications in neonatal resuscitation：epinephrine and the search for better alternative strategies. Clin　Perinatol， 2012， 39 （4）：843-855.
20. 　Jerath N， Frndova H， Mccrindle BW， et al. Clinical impact of vasopressin infusion on hemodynamics， liver and renal function in pediatric　patients. Intensive Care Med， 2008， 34 （7）：1274-1280.
21. 　Cheung DC， Gill RS， Liu JQ， et al. Vasopressin improves systemic hemodynamics without compromising mesenteric perfusion in the resuscitation of asphyxiated newborn piglets：a dose-response study. Intensive Care Med， 2012， 38 （3）：491-498.
22. 　Narayen G， Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab， 2012， 16 （2）：183-191.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research Progress of Arginine Vasopressin

Abstract Full text Figures/Tables Video References Cited by

Format

Content